Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Colorcon
AstraZeneca
Medtronic
Baxter

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,528,540

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 6,528,540 protect, and when does it expire?

Patent 6,528,540 protects ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, BREVIBLOC, BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, and BREVIBLOC IN PLASTIC CONTAINER, and is included in two NDAs.

Protection for BREVIBLOC has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-six patent family members in twenty-four countries.

Summary for Patent: 6,528,540
Title: Esmolol formulation
Abstract:An aqueous, sterile pharmaceutical composition suitable for parenteral administration for the treatment of cardiac conditions, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride (esmolol hydrochloride), a buffering agent and an osmotic-adjusting agent, as well as a method for its manufacture, are disclosed.
Inventor(s): Liu; Jie (Scotch Plains, NJ), Pejaver; Satish K. (Bridgewater, NJ), Owoo; George (North Plainfield, NJ)
Assignee: Baxter International Inc. (Deerfield, IL)
Application Number:10/016,260
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,528,540
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form; Formulation; Process;

Drugs Protected by US Patent 6,528,540

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Hq Spclt Pharma ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER esmolol hydrochloride SOLUTION;INTRAVENOUS 205703-002 Apr 7, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Hq Spclt Pharma ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER esmolol hydrochloride SOLUTION;INTRAVENOUS 205703-001 Apr 7, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-006 Feb 25, 2003 AP RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-007 May 28, 2003 DISCN No No   Start Trial   Start Trial Y   Start Trial
Baxter Hlthcare BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER esmolol hydrochloride INJECTABLE;INJECTION 019386-005 Jan 27, 2003 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Baxter Hlthcare BREVIBLOC IN PLASTIC CONTAINER esmolol hydrochloride INJECTABLE;INJECTION 019386-004 Feb 16, 2001 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,528,540

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 035416   Start Trial
Argentina 098013   Start Trial
Austria 341319   Start Trial
Australia 2002309475   Start Trial
Brazil 0203517   Start Trial
Canada 2410446   Start Trial
China 1298320   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Medtronic
Merck
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.